Home
February 2010 March 2010 April 2010
Su Mo Tu We Th Fr Sa
Week 9 1 2 3 4 5 6
Week 10 7 8 9 10 11 12 13
Week 11 14 15 16 17 18 19 20
Week 12 21 22 23 24 25 26 27
Week 13 28 29 30 31
Reach urologists

Hormonal testing and pharmacologic treatment of erectile dysfunction: A clinical practice guideline from the American College of Physicians - Abstract Show Comments PDF Print E-mail
  
Thursday, 26 November 2009

The American College of Physicians and University of Pennsylvania, Philadelphia, Pennsylvania.

University of Colorado, Aurora, Colorado; Atlantic Health, Morristown, New Jersey; Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, California; Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California.

The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment.

Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006). The literature search was updated by searching for articles in MEDLINE and EMBASE published between May 2007 and April 2009. Searches were limited to English-language publications. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system.

Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence).

Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence).

Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).

Written by:
Qaseem A, Snow V, Denberg TD, Casey DE Jr, Forciea MA, Owens DK, Shekelle P.   Are you the author?

Reference:
Ann Intern Med. 2009 Oct 19. Epub ahead of print.

PubMed Abstract
PMID:19843532

UroToday.com Erectile Dysfunction (ED) Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 0
PoorBest


 

Bookmark and Share
< Prev   Next >

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts



Featured Conference

Media and Publisher

Advertising Rates

Working with Industry

Case Studies
Sponsorship Opportunities

Erectile Dysfunction
Sponsored By